NCT07706842
Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes
Not Yet Recruiting · Not specified · Ataraxis AI, Inc. · registry updated 2026-10-06
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.
Inclusion
- Aged 18 years or older at the time of consent.
- Diagnosis of a solid tumor malignancy, confirmed histologically or cytologically.
- Patient is undergoing Ataraxis testing as part of their routine clinical care.
- Availability of a pathology specimen.
- Willing and able to provide written informed consent.
Exclusion
- Unable or unwilling to provide informed consent.
- Patient for whom an Ataraxis test result was not successfully generated (e.g., due to sample quality, technical failure, or any reason resulting in a non-reportable result).